Liquid biopsies helpful in prostate cancer, but most not ready for routine use

Reuters Health - 29/01/2021 - Liquid biopsies have the potential to guide therapeutic decision making in prostate cancer, but issues such as assay standardization, cost and accessibility need to be addressed before they can be implemented in routine practice, researchers say. "There are many different technologies to interrogate tumor features from liquid biopsies," Dr. Joaquin Mateo of Vall d'Hebron University Hospital in Barcelona told Reuters Health by email. "Some of them have already been validated and received regulatory clearance, such as CTC counts, but many are in development." "It is critical that we integrate these technologies into clinical trials so we can accelerate their development," he said. "Hence, there is a need for all stakeholders - academic institutions, pharmaceutical and biotech companies - to push together for validating and clinically qualifying these novel biomarkers, so we can use them properly to improve patient care." "Clinician...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 29 January, 20213 February, 2021